CTLA4 and neoplasm: One is that the AE17M tumor model did not respond to intravenous (i.v.)immunotoxins; thus, we were unable to evaluate whether i.v. immunotoxin sensitizes tumors to the therapeutic effect of anti-CTLA-4.